Pipeline

New first-line lung data is positive for Merck's Keytruda, but competitor looms large

New first-line lung data is positive for Merck's Keytruda, but competitor looms large

By

A trial studying Keytruda met its endpoint in first-line lung cancer patients.

Five things for pharma marketers to know: Monday, June 13, 2016

Five things for pharma marketers to know: Monday, June 13, 2016

By By

A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs

Bristol-Myers Squibb's Yervoy, Opdivo combo data confers edge in lung cancer

Bristol-Myers Squibb's Yervoy, Opdivo combo data confers edge in lung cancer

By

Investors said a combination of Opdivo and Yervoy is the top-performing regimen in a niche of non-small cell lung-cancer patients.

ASCO 2016 Preview: Expect data on CDK inhibitors, CAR-T therapies, and pricing

ASCO 2016 Preview: Expect data on CDK inhibitors, CAR-T therapies, and pricing

By

Competition among new breast cancer drugs, an immunotherapy contender, and pricing discussions headline one of the biggest cancer conferences of the year.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

By

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

Drugmakers renew interest in antibiotic development

Drugmakers renew interest in antibiotic development

By

The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.

Five things for pharma marketers to know: Wednesday, May 18, 2016

Five things for pharma marketers to know: Wednesday, May 18, 2016

By

Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year

With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

By

The bar for market success has been set high for baricitinib.

Five things for pharma marketers to know: Tuesday, May 3, 2016

Five things for pharma marketers to know: Tuesday, May 3, 2016

By

IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service

Five things for pharma marketers to know: Friday, April 22, 2016

Five things for pharma marketers to know: Friday, April 22, 2016

By

AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying

Five things for pharma marketers to know: Wednesday, April 20, 2016

Five things for pharma marketers to know: Wednesday, April 20, 2016

By

Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance

Five things for pharma marketers to know: Wednesday, March 30, 2016

Five things for pharma marketers to know: Wednesday, March 30, 2016

By

There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson's disease drug; Bloomberg funds new immunotherapy center

Drugmakers move to counteract expiring patents with new respiratory drugs

Drugmakers move to counteract expiring patents with new respiratory drugs

By

Symptom-driven care is falling out of fa­vor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.

Corbus bets on cystic-fibrosis market with Resunab

Corbus bets on cystic-fibrosis market with Resunab

By

Current treatments, including steroids and ibuprofen, help control symptoms. But the side-effect profiles are difficult for patients to manage.

Five things for pharma marketers to know: Monday, March 7, 2016

Five things for pharma marketers to know: Monday, March 7, 2016

By

European regulators launch speedier drug approval process: AbbVie and Boehringer Ingelheim to partner on psoriasis drug; the FDA approves hemophilia B drug

Five things for pharma marketers to know: Friday, February 26, 2016

Five things for pharma marketers to know: Friday, February 26, 2016

By

Bristol-Myers Squibb considered immunotherapy market leader; McKesson buys two cancer-care companies; Bayer names new CEO

With support of FDA committee, Remicade biosimilar edges closer to market

With support of FDA committee, Remicade biosimilar edges closer to market

By

The FDA is set to announce its decision on the drug in April.

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Health economic and outcomes research datasets have rarely been integral to product development and communication plans.

Five things for pharma marketers to know: Friday, January 29, 2016

Five things for pharma marketers to know: Friday, January 29, 2016

By

FDA approves Merck's HCV doublet regimen; Gilead CEO steps down; Clinton takes aim at Valeant price hikes

Top 25 metabolic products, 2014-2015

Sanofi is the category leader. Its product, Lantus Solostar, brought in $5.27 billion in US sales between October 2014 and September 2015.

Diabetes R&D narrows in on glycemic control

Diabetes R&D narrows in on glycemic control

By

New entrants in the type 2 diabetes treatment market share a similar goal: To solve patients' constant struggle with glycemic control.

Marketing challenges remain in crowded metabolic market

Marketing challenges remain in crowded metabolic market

By

Experts insist that R&D efforts in the category must mirror educational campaigns and lifestyle changes, and quickly.

Five things for pharma marketers to know: Friday, January 22, 2016

Five things for pharma marketers to know: Friday, January 22, 2016

By

NICE recommends Opdivo for skin cancer; Sanofi layoffs could be looming; Senators ask for feedback on Sovaldi investigation

Five things for pharma marketers to know: Wednesday, January 13, 2016

Five things for pharma marketers to know: Wednesday, January 13, 2016

By

Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup

New multiple myeloma drugs prompt cost-effectiveness report

New multiple myeloma drugs prompt cost-effectiveness report

By

The FDA in November approved three new drugs that treat the rare blood cancer.

Five things for pharma marketers to know: Friday, January 8, 2016

Five things for pharma marketers to know: Friday, January 8, 2016

By

GSK will stop using outside doctors to promote its drugs; Roche will file its immuno-oncology drug for approval; Mylan inks deal to develop six biosimilars

Five things for pharma marketers to know: Tuesday, January 5, 2016

Five things for pharma marketers to know: Tuesday, January 5, 2016

By

Gilead's hep-C combo gets Breakthrough designation; Baxalta licences experimental cancer drugs; Novartis agrees to settle class-action lawsuit

New cardiovascular drugs raise concerns about pricing, efficacy

New cardiovascular drugs raise concerns about pricing, efficacy

By

With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.

Five things for pharma marketers to know: Friday, December 18, 2015

Five things for pharma marketers to know: Friday, December 18, 2015

By

GlaxoSmithKline buys Bristol-Myers Squibb's research assets; Gilead Sciences makes large stake in experimental rheumatoid arthritis drug; Avandia's REMS program ends

Lantus competitor receives FDA approval

Lantus competitor receives FDA approval

By

Eli Lilly and Boehringer Ingelheim received approval to begin selling their Lantus knock-off drug after settling a patent lawsuit with Sanofi in September.

OPINION

Email Newsletters